BioSpace News Archive

Unravel Biosciences, Inc., (“Unravel”), an AI-enabled therapeutics company established to advance drugs for complex diseases, today announced that it has received Orphan Drug Designation from the United States Food and Drug Administration (FDA) for vorinostat (RVL-001) as a treatment for Rett Syndrome.

The Bill & Melinda Gates Medical Research Institute announced the appointment of Patrice Matchaba, MD, as Chief Executive Officer, starting June 10, 2024.

Evotec SE has announced the extension of its 20-year collaboration with CHDI Foundation, Inc. CHDI is a privately funded nonprofit biomedical research organisation exclusively dedicated to collaboratively developing therapeutics that will substantially improve the lives of those affected by Huntington’s disease.

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announced the submission of three patents to the European Patent Office.

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology Annual Meeting 2024.

Genovate Biotechnology Co., Ltd. announced its plans to submit a New Drug Application with the United States Food and Drug Administration for PMR, an investigational once daily extended-release form of cilostazol for the treatment of Intermittent Claudication, in the second half of 2025.

selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T cell-mediated autoimmune diseases, announced the initiation of a Phase 1b trial with its lead compound si-544 in adult patients with psoriasis vulgaris or psoriatic arthritis.

Sapreme, a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors.

Terumo Cardiovascular, a global leader in cardiovascular surgery technologies, announced that the U.S. Food and Drug Administration has granted 510 clearance for the CDI OneView Monitoring System.